Takeda (TAK) Reports $6.98B Q4 Sales Missing Estimates

Takeda Pharmaceutical Company Ltd. (NYSE: TAK) reported fourth-quarter sales of $6.98 billion, falling short of Wall Street's $7.05 billion estimates. The company posted adjusted earnings of 28 cents per ADR, exceeding analyst forecasts of 21 cents per share. CFO Milano Furuta indicated a focus on profitability and cash flow, despite revenue challenges, while planning multiple product launches. For fiscal 2026, Takeda forecasts adjusted earnings of 31 cents per share and sales of $29.58 billion, demonstrating a commitment to growth through operations transformation and pipeline advancement.